Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission

Virology

Volumn 387, Issue 2, 2009, Pages 388-394

  Samleerat, Tanawan ^a,b   Thenin, Suzie ^a   Jourdain, Gonzague ^c,d   Ngo Giang Huong, Nicole ^c,d   Moreau, Alain ^a   Leechanachai, Pranee ^b   Ithisuknanth, Jirapan ^e   Pagdi, Karin ^f   Wannarit, Pornpun ^f   Sangsawang, Suraphan ^g   Lallemant, Marc ^c,d   Barin, Francis ^a   Braibant, Martine ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Institute of research for development Thailand   (Thailand)

^e Banglamung Hospital   (Thailand)

^f Provincial Hospital   (Thailand)

^g Health Promotion Center   (Thailand)

Author keywords

HIV; Mother to child transmission; Neutralizing antibodies

Indexed keywords

AMINO ACID; CHLORMETHINE; ENVELOPE PROTEIN; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; ZIDOVUDINE;

ADULT; ARTICLE; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; SEROTYPE; VERTICAL TRANSMISSION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; THAILAND;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 64849106636     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.02.024     Document Type: Article

References (27)

1. Ahmad N., Baroudy B.M., Baker R.C., and Chappey C. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J. Virol. 69 2 (1995) 1001-1012
2. Barin F., Brunet S., Brand D., Moog C., Peyre R., Damond F., Charneau P., and Barre-Sinoussi F. Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors. J. Infect. Dis. 189 2 (2004) 322-327
3. Barin F., Jourdain G., Brunet S., Ngo-Giang-Huong N., Weerawatgoompa S., Karnchanamayul W., Ariyadej S., Hansudewechakul R., Achalapong J., Yuthavisuthi P., Ngampiyaskul C., Bhakeecheep S., Hemwutthiphan C., and Lallemant M. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J. Infect. Dis. 193 11 (2006) 1504-1511
4. Bongertz V., Costa C.I., Veloso V.G., Grinsztejn B., Joao Filho E.C., Calvet G., Pilotto J.H., Guimaraes M.L., and Morgado M.G. Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity. Scand. J. Immunol. 53 3 (2001) 302-309
5. Braibant M., Brunet S., Costagliola D., Rouzioux C., Agut H., Katinger H., Autran B., and Barin F. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 20 15 (2006) 1923-1930
6. Brand D., Bebydefaux A., Mace M., Brunet S., Moreau A., Godet C., Jais X., Cazein F., Semaille C., and Barin F. First identification of HIV-1 groups M and O dual infections in Europe. Aids 18 18 (2004) 2425-2428
7. Charneau P., Mirambeau G., Roux P., Paulous S., Buc H., and Clavel F. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 241 5 (1994) 651-662
8. Connor R.I., Chen B.K., Choe S., and Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206 2 (1995) 935-944
9. Dickover R., Garratty E., Yusim K., Miller C., Korber B., and Bryson Y. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J. Virol. 80 13 (2006) 6525-6533
10. Englund J., Glezen W.P., and Piedra P.A. Maternal immunization against viral disease. Vaccine 16 14-15 (1998) 1456-1463
11. Hengel R.L., Kennedy M.S., Steketee R.W., Thea D.M., Abrams E.J., Lambert G., and McDougal J.S. Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS Res. Hum. Retrovir. 14 6 (1998) 475-481
12. Lallemant M., Jourdain G., Le Coeur S., Kim S., Koetsawang S., Comeau A.M., Phoolcharoen W., Essex M., McIntosh K., and Vithayasai V. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N. Engl. J. Med. 343 14 (2000) 982-991
13. Lathey J.L., Tsou J., Brinker K., Hsia K., Meyer III W.A., and Spector S.A. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J. Infect. Dis. 180 2 (1999) 344-350
14. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., and Kayman S.C. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78 10 (2004) 5205-5215
15. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., and Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72 4 (1998) 2855-2864
16. Rong R., Bibollet-Ruche F., Mulenga J., Allen S., Blackwell J.L., and Derdeyn C.A. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 81 3 (2007) 1350-1359
17. Safrit J.T., Ruprecht R., Ferrantelli F., Xu W., Kitabwalla M., Van Rompay K., Marthas M., Haigwood N., Mascola J.R., Luzuriaga K., Jones S.A., Mathieson B.J., and Newell M.L. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J. Acquir. Immune. Defic. Syndr. 35 2 (2004) 169-177
18. Sagar M., Wu X., Lee S., and Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80 19 (2006) 9586-9598
19. Samleerat T., Braibant M., Jourdain G., Moreau A., Ngo-Giang-Huong N., Leechanachai P., Hemvuttiphan J., Hinjiranandana T., Changchit T., Warachit B., Suraseranivong V., Lallemant M., and Barin F. Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE. J. Infect. Dis. 198 6 (2008) 868-876
20. Scarlatti G., Albert J., Rossi P., Hodara V., Biraghi P., Muggiasca L., and Fenyo E.M. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J. Infect. Dis. 168 1 (1993) 207-210
21. Shibata J., Yoshimura K., Honda A., Koito A., Murakami T., and Matsushita S. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J. Virol. 81 8 (2007) 3757-3768
22. Verhofstede C., Demecheleer E., De Cabooter N., Gaillard P., Mwanyumba F., Claeys P., Chohan V., Mandaliya K., Temmerman M., and Plum J. Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J. Virol. 77 5 (2003) 3050-3057
23. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 6 (2002) 1896-1905
24. Wolinsky S.M., Wike C.M., Korber B.T., Hutto C., Parks W.P., Rosenblum L.L., Kunstman K.J., Furtado M.R., and Munoz J.L. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255 5048 (1992) 1134-1137
25. Wolk T., and Schreiber M. N-glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. 195 3 (2006) 165-172
26. Wu X., Parast A.B., Richardson B.A., Nduati R., John-Stewart G., Mbori-Ngacha D., Rainwater S.M., and Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80 2 (2006) 835-844
27. Zhang M., Gaschen B., Blay W., Foley B., Haigwood N., Kuiken C., and Korber B. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14 12 (2004) 1229-1246